Walter Flamenbaum

Uman Pharma, Inc. develops, manufactures, and markets generic injectable pharmaceutical products. The company was founded in December 20, 2007 and is headquartered in Montreal, Canada.

Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France.

Part of HgCapital LLP, Plumtree Group Ltd. is a British company that develops and distributes electronic document management software. The private company is based in Keyworth, UK. Plumtree Group was acquired by Ideagen Ltd. (United Kingdom), part of HgCapital LLP from July 07, 2022 on December 17, 2012 for $4.03 million.

Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then.